Insulet Co. (NASDAQ:PODD) Shares Bought by Public Sector Pension Investment Board

Public Sector Pension Investment Board increased its holdings in shares of Insulet Co. (NASDAQ:PODD) by 14.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,099 shares of the medical instruments supplier’s stock after acquiring an additional 400 shares during the quarter. Public Sector Pension Investment Board’s holdings in Insulet were worth $721,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in PODD. Blue Trust Inc. lifted its stake in shares of Insulet by 84.1% in the 3rd quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock worth $30,000 after acquiring an additional 58 shares during the period. Venturi Wealth Management LLC lifted its holdings in Insulet by 633.3% in the 3rd quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier’s stock valued at $36,000 after acquiring an additional 133 shares during the last quarter. International Assets Investment Management LLC bought a new position in shares of Insulet during the 2nd quarter valued at about $32,000. UMB Bank n.a. grew its stake in shares of Insulet by 81.0% in the 2nd quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier’s stock worth $37,000 after purchasing an additional 81 shares during the last quarter. Finally, 1620 Investment Advisors Inc. bought a new position in shares of Insulet in the second quarter valued at $52,000.

Analyst Ratings Changes

Several research analysts have recently weighed in on PODD shares. BTIG Research lifted their target price on shares of Insulet from $260.00 to $270.00 and gave the stock a “buy” rating in a research report on Friday, November 8th. Sanford C. Bernstein started coverage on shares of Insulet in a report on Wednesday, November 6th. They set an “outperform” rating and a $300.00 price target for the company. Barclays upped their price objective on shares of Insulet from $220.00 to $234.00 and gave the company an “equal weight” rating in a research note on Monday, November 11th. Piper Sandler lifted their target price on shares of Insulet from $230.00 to $285.00 and gave the company an “overweight” rating in a research note on Tuesday, September 17th. Finally, Raymond James upped their price target on shares of Insulet from $213.00 to $260.00 and gave the stock an “outperform” rating in a research note on Monday, October 14th. Three research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $253.27.

Insulet Trading Down 0.8 %

NASDAQ:PODD opened at $265.46 on Friday. The company’s 50 day moving average is $247.48 and its 200-day moving average is $217.06. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. Insulet Co. has a 12 month low of $160.19 and a 12 month high of $279.40. The firm has a market cap of $18.62 billion, a price-to-earnings ratio of 45.46, a P/E/G ratio of 4.12 and a beta of 1.21.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.